Main Structure of HitGen Global Drug R&D and Production Base (Phase I) Project Successfully Completed Release Time：2025-12-30

On December 25, 2025, HitGen Inc. (hereinafter referred to as "HitGen", SSE: 688222.SH), held a ceremony to celebrate the completion of the main structure for its Global Drug R&D and Production Base (Phase I) project (hereinafter referred to as the "Base" or "Project") at the Chengdu Tianfu International Bio-town. Dr. Jin Li, Chairman and CEO of HitGen, along with company board directors, heads of departments and employee representatives, as well as representatives from construction partners and other distinguished guests, jointly witnessed this milestone moment.

Situated in the core area of Chengdu Tianfu International Bio-town, HitGen's Global Drug R&D and Production Base spans approximately 55 mu (about 36,667 square meters) with a total floor area of around 116,000 square meters. It is designed to establish a comprehensive and integrated drug R&D and production base featuring a full spectrum of research capabilities and technology platforms covering target biology, structural biology, synthetic and medicinal chemistry, computational sciences, in vitro and in vivo biology, and translational sciences, which combines scientific experience and expertise with automation, big data and AI, while emphasizing advanced technologies, safety, and environmental sustainability. Upon completion, it will not only significantly enhance the company's independent innovation capabilities and full-chain service capacity in drug discovery and development, but also become a landmark within Tianfu International Bio-town and the wider local biopharmaceutical sector, injecting strong momentum into regional industry development.

During the ceremony, Dr. Jin Li, Chairman and CEO of HitGen, expressed his sincere gratitude to all parties involved in the Project's construction. He stated: "The completion of the main structure represents not only a key milestone in the Project's progress, but also a solid step forward in HitGen's pursuit of its vision of 'building a world-leading innovative biopharmaceutical enterprise contributing to better life and health of mankind' and its mission of 'focusing on drug discovery to alleviate human suffering'. We will uphold the principle of 'Safety First, Quality Foremost', maintain strict quality control to ensure smooth completion and commissioning, and develop the Base into a platform that gathers innovative wisdom, refines professional expertise, and cultivates top-tier talent."

Representatives from the construction partners introduced the overall progress of the Project, technical challenges, and innovative building technologies, while highlighting the achievements in quality control, safety management, and standardization.

Upon Dr. Jin Li's commencement command, on-site workers poured the final batch of concrete, marking the full completion of the main structure. All guests present shared in the significance and joy of this moment.

The successful completion of the main structure signals a new phase in the Base's overall construction. HitGen will continue to advance follow-up work and equipment installation to strive for operational readiness, thereby providing comprehensive support for the company's business development. Moving forward, with the capability upgrade brought about by the Base, HitGen is confident in securing a more prominent position on the global innovative drug discovery and development landscape and contributing further to industry advancement.

About HitGen Inc.

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid-based drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Meanwhile, we are developing a DEL+AI+ Automated DMTA (Design-Make-Test-Analyze) molecular optimization platform to accelerate the discovery and optimization process of preclinical candidate compounds. Through our diverse and flexible business models, we have built up collaboration partnerships with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.